嵌合抗原受体(CAR)T细胞毒性管理:面向急诊医护的综述与指南
本文为面向急诊医护的综述与指南,总结CAR T细胞治疗后常见急诊就诊表现,重点为细胞因子释放综合征(CRS)与CAR T细胞相关神经毒性的评估与处理。CAR T细胞治疗虽在晚期癌症显示初步成功,但急性毒性发生风险高,CRS与神经毒性最常报告,可导致终末器官损伤、急性失代偿或影响原发恶性肿瘤治疗延续。处理依毒性严重程度而定,通常从严密支持治疗开始,若毒性判定为高严重度,可能包括给予托珠单抗并可能使用大剂量糖皮质激素。随着CAR T细胞治疗应用增多,急诊医生需认识这些潜在毒性以快速诊断和处理。
要点
- CAR T细胞治疗后急性毒性发生风险高,CRS与神经毒性最常报告,急诊医生应警惕此类患者。
- 毒性可导致终末器官损伤,并可能急性危及患者或影响其原发恶性肿瘤治疗的延续。
- 处理依毒性严重程度而定,通常从严密支持治疗开始。
- 若毒性判定为高严重度,治疗可能包括托珠单抗并可能使用大剂量糖皮质激素。
- 急诊医生需认识这些潜在毒性,以快速诊断和处理正在接受CAR T细胞治疗的患者。
适用人群与场景
- 正在接受或曾接受CAR T细胞治疗、因相关不良事件就诊于急诊的患者。
处置流程与药物剂量
- 依毒性严重程度决定处理:通常从严密支持治疗开始。
- 若毒性判定为高严重度,可能给予托珠单抗,并可能使用大剂量糖皮质激素。
红旗征与不能漏的情况
- CRS与神经毒性可导致终末器官损伤,并可能急性危及患者或影响其原发恶性肿瘤治疗的延续。
研究设计与关键结果
- 本综述与指南回顾相关研究与临床指南,并附一例病例,详细复习CRS与神经毒性的评估与处理。
证据类型、等级与局限
- 证据类型:综述与指南(面向急诊医护)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 急诊医生应认识CAR T细胞治疗后的CRS与神经毒性,以快速诊断和处理此类患者。
- 处理依毒性严重程度分层:通常从严密支持治疗开始,高严重度时可能包括托珠单抗并可能使用大剂量糖皮质激素。
指南或共识出处
- Management of Chimeric Antigen Receptor (CAR) T-Cell Toxicities: A Review and Guideline for Emergency Providers(J Emerg Med)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy is an adoptive cellular immunotherapy that is being utilized more frequently due to its initial success in advanced-stage cancers. Unfortunately, CAR T-cell therapy is often associated with acute systemic toxicities, including cytokine release syndrome (CRS) and CAR T-cell-associated neurotoxicity (neurotoxicity).
OBJECTIVE: We created a review that addresses the potential common emergency department (ED) presentations associated with CAR T-cell therapy. We reviewed the relevant research and clinical guidelines to develop a guide tailored toward addressing the needs of the emergency medicine community to manage these complications. In addition, a case is presented and the evaluation and management of CRS and neurotoxicity are reviewed in detail.
DISCUSSION: Despite CAR T-cell designs showing promising results, the risk of acquiring an acute toxicity is high, with CRS and neurotoxicity reported most often. The systemic toxicities associated with these adverse events can lead to end-organ damage and compromise the patient acutely or jeopardize the continuation in treatment of their underlying malignancy. Depending on the severity of the toxicity, treatment typically starts with vigilant supportive care, but may include administration of tocilizumab and possibly high-dose corticosteroids if the toxicity is deemed of high severity.
CONCLUSIONS: With the increasing administration of CAR T-cell therapy, emergency physicians will likely encounter more patients with associated adverse events, including CRS and neurotoxicity. It is increasingly important that emergency physicians are aware of these potential toxicities in order to rapidly diagnose and treat patients undergoing CAR T-cell therapy.
参考来源
- Gupta R, Roach C, Hryniewicki AT, et al. Management of Chimeric Antigen Receptor (CAR) T-Cell Toxicities: A Review and Guideline for Emergency Providers. J Emerg Med. 2020. PMID: 32473867. doi:10.1016/j.jemermed.2020.04.021
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。